Showing 1881-1890 of 2893 results for "".
- ASDS Abstract Examines Black Women’s Aesthetic Concernshttps://modernaesthetics.com/news/asds-abstract-examines-black-womens-aesthetic-concerns/2473705/Patients’ concerns and desires can vary based on various demographics, so understanding the interests of Black women was the focus of a top-10 abstract presented by Michelle Henry, MD, at the 2024 American Society for Dermatologic Surgery (ASDS) Annual Meeting. Dr. Henry presented
- ASDS Abstract Highlights Potential of ALA-PDThttps://modernaesthetics.com/news/asds-abstract-highlights-potential-of-ala-pdt/2473704/Photodynamic therapy (PDT) with aminolevulonic acid (ALA) was the topic of the top 10 abstract “Fine Wrinkles and the Art of Light,” presented by Luke Horton, MD, at the 2024 American Society for Dermatologic Surgery (ASDS) Annual Meeting. Dr. Horton performed a study along
- DefenAge Skincare Launches 12-Factor Revitalizing Lip Enhancerhttps://modernaesthetics.com/news/defenage-skincare-launches-12-factor-revitalizing-lip-enhancer/2473701/DefenAge Skincare introduces a “revolutionary, first-of-its kind” anti-aging serum for fuller, smoother and more youthful lips. The 12-Factor Revitalizing Lip Enhancer is powered by DefenAge’s patented Age-Repair Defensins. The lip serum is designed to rejuvenate lip a
- Study Backs CP-GEP Tests’ Accuracyhttps://modernaesthetics.com/news/study-backs-cp-gep-tests-accuracy/2473699/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the S
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea
- Avène Introduces Two New Topical Solutionshttps://modernaesthetics.com/news/avene-introduces-two-new-topical-solutions/2473697/French skincare brand Avène introduced Cicalfate+ Intensive Skin Restoration Serum and XeraCalm Eczema Calming Relief Balm, two new innovations that feature the company’s mineral-rich Thermal Spring Water. “These breakthrough formulations are at the heart of how Eau T
- Botox Approved for Platysma Bandshttps://modernaesthetics.com/news/botox-approved-for-platysma-bands/2473696/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a pres
- JOYA Launches First Skin Cancer Prevention, Anti-Aging Employee Benefit Platformhttps://modernaesthetics.com/news/joya-launches-first-skin-cancer-prevention-anti-aging-employee-benefit-platform/2473695/JOYA the first employee skin health and wellness benefit platform, announced its emergence from stealth mode with $5 million in seed funding from LUX Capital, Mosaic General Partnership, Arsama Trust, and Joyance Partners. The funding will support team expansion, product developme
- L&P Aesthetics Earns Distinction for Signature Deep-Plane Facelifthttps://modernaesthetics.com/news/lp-aesthetics-earns-distinction-for-signature-deep-plane-facelift/2473692/L&P Aesthetics, located in Palo Alto and Los Gatos, California, was named Best Facial Plastic Surgery in Silicon Valley Magazine's Best of 2024. The magazine recognized the "refined approach" to the practice’s L&P Signature deep-plane facelift, which lif
- FDA Clears Accure Laser System for Acne Vulgarishttps://modernaesthetics.com/news/fda-clears-accure-laser-system-for-acne-vulgaris/2473691/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founde